Daily Biotech Movers — 2026-10-19: Broad Breadth, Biotech Beating Its Own Sector Proxy, and Extremes Set by Two Binary Clinical Readouts

Monday, October 19, 2026 was the mirror image of the prior session in direction and its near-opposite in texture. Across ~570 tracked public biotech and life-sciences companies, 557 carried a directional print — 333 finished higher against 224 lower, a 1.49-to-1 advancer-to-decliner ratio — and 13 names had no usable daily percentage change. The median move was +0.85% and the mean +0.69%, on a standard deviation of 6.19%. The average advancer gained +3.48% while the average decliner lost -3.44%, a near-perfect symmetry that says the day pulled in both directions rather than lifting everything. 118 names cleared the anomaly filter, 106 moved at least 5% — 62 of them up, 44 down — and the spread between the best and worst print was 124.1 percentage points: Disc Medicine +38.86% at one end and EyePoint -85.28% at the other.

The macro tape was unremarkable; the biotech tape was not. The S&P 500 added +0.44% and the broad biotech proxy (IBB) +1.02%, but the equal-weighted small-cap biotech proxy (XBI) rose +2.45% while the health care sector proxy (XLV) fell -0.60%. That configuration is the most informative single fact of the session: biotech outperformed its own sector proxy by 3.05 percentage points and the S&P 500 by 2.01 points, and it did so while the larger, more defensive health care complex — big pharma, medtech, managed care — sold off. Money was not rotating into health care on Monday. It was rotating through it, out of the large-cap defensive end and into the clinical-stage end. Inside our own universe the same shape appears in the sector averages: the most clinical buckets led — Genetics & Genomics +5.47% (n=6), Antibodies +2.66% (n=42), RNA, Peptide & Gene Therapy +2.41% (n=27) and Biologics +1.66% (n=84) — while Diagnostics finished -1.18% (n=28), Drug Delivery/Formulation -0.64% (n=28) and Non-Pharmaceutical Biotech -0.32% (n=17).

So the organising fact of the day is not that biotech rose. It is that the breadth was genuinely broad (+0.85% median, 1.49-to-1 advancers, 62 of 106 large moves on the upside) and yet the leaderboard’s extremes had almost nothing to do with that breadth. The two largest moves in either direction were the two halves of the same experiment — a pivotal-win gap higher and a pivotal-loss collapse — and four of the six names at the top and bottom of the board carried no same-day company disclosure at all. When a sector rises two and a half percent and its two biggest prints are +39% and -85%, the index number is describing liquidity and risk appetite while the leaderboard is describing idiosyncratic clinical risk. The breadth tells you what the asset class did. The extremes tell you what single-event biotech is.

The 6 Classes of Mover Signal

Every anomaly-flagged move is assigned to one of six classes, and the class is what separates information from mechanics. Class 1 — halt-release: a name resumes trading after a regulatory or news halt and gaps to a new equilibrium. Class 2 — single-stock binary catalyst: a clinical readout, regulatory decision or program failure resets the equity’s entire valuation in one session. Class 3 — buyout and strategic capital: an acquisition, merger, tender or strategic financing reprices the float against a control value. Class 4 — sector rotation: the name moves with its bucket rather than its own news. Class 5 — sell-the-news: a positive disclosure is sold because the outcome was already in the price. Class 6 — stealth accumulation or distribution: the price barely moves while turnover runs multiples of normal, which is the footprint of size changing hands quietly.

Monday’s board was dominated by Class 2 and by the absence of any class at all. Two of the six extremes were pure Class 2 events, and they were the only two names on the leaderboard with a same-day, company-specific, valuation-changing disclosure: Disc Medicine’s APOLLO Phase 3 win and EyePoint’s DURAVYU Phase 3 failure. A third, Lucid Diagnostics, sits at the intersection of Class 2 and Class 6 — a week-old listing-compliance notice and a slow-motion repricing on double normal turnover with no fresh filing. The other three — Nautilus Biotechnology, Adagio Medical and Lunai Bioworks — are flagged as having no clean same-day catalyst: their moves are real, their volume is real in two of the three cases, but no Monday disclosure explains them. There was no Class 1 halt-release on the board, no Class 3 control event, and — this is the tell — almost no Class 4. On a day when the small-cap proxy rose 2.45%, only a handful of the anomaly names were simply riding beta; the rest were either event-driven or untethered.

That distribution is itself the signal. A rotation day produces a leaderboard full of Class 4 names, clustered by bucket, with unremarkable individual volume. Monday produced the opposite: a broad up-day whose extremes were overwhelmingly idiosyncratic, with the largest relative volume print in the entire dataset (56.09x) attached to a company that lost 85% of its value on a failed trial, and the second largest (13.29x) attached to a company that gained 39% on a successful one. Breadth was the tide; the leaderboard was two boats.

Top 3 Winners — What Drove Them

IRON — Disc Medicine, +38.86% to $78.93 on 13.29x volume

Disc Medicine closed at $78.93, up 38.86% from $56.85, on 8.49 million shares — a 13.29x ratio against its 30-day average and the second-heaviest relative print on the board. The catalyst was as clean as biotech gets: a Sunday-night announcement that the company would host a webcast at 8:00 a.m. ET Monday to report topline results from the pivotal APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), a rare inherited disorder in which accumulated protoporphyrin causes acute, painful photosensitivity. APOLLO hit every primary and secondary endpoint, and the company is now pointing to an NDA submission in late 2026 (AInvest — Disc Medicine: bitopertin’s make-or-break readout lands Monday, RTTNews — Disc Medicine set to report Phase 3 bitopertin results in rare blood disorder, Invezz — Disc Medicine stock soars: take profit or buy into strength?, Simply Wall St — Disc Medicine hits Phase 3 goals, is the stock still cheap?).

The magnitude only makes sense against the setup. IRON had slid from the mid-$60s in late September to the mid-$50s, and was still -8.4% over the five sessions into the print — a stock de-rating ahead of the single binary event the entire equity was priced against. A 39% gap on a de-risked binary is not a re-rating of the franchise; it is the removal of a discount. The stock closed at $78.93 inside a recorded 52-week range of $40.00–$99.50, roughly two-thirds of the way up that band and still below its own high, which is what a readout-driven repricing looks like when the market had already marked the probability of failure into the price. Its Antibodies bucket averaged +2.66% (n=42), and IRON beat it by 36.2 points. Class 2 — single-stock binary catalyst.

NAUT — Nautilus Biotechnology, +27.67% to $2.63 on 2.08x volume

Nautilus Biotechnology closed at $2.63, up 27.67% from $2.06, on 14.92 million shares — a 2.08x volume ratio — after a -8.4% five-day decline. No same-day press release, filing or data disclosure was identified. The analyst coverage being recycled across Monday’s auto-generated market summaries is stale, and the date stamps matter: Roth Capital’s Buy initiation with a $3.50 target published roughly twenty days earlier, and Leerink’s Outperform with a $4 target five weeks before that (TheFly — Nautilus Biotechnology initiated with a Buy at Roth Capital, TheFly — Nautilus Biotechnology initiated with an Outperform at Leerink). A twenty-day-old initiation does not produce a 28% single-session move.

What the live calendar does contain is thin and mostly two-sided. Third-quarter results are scheduled for October 27, one week out, and a $300 million mixed-shelf registration was filed September 11 — a dilution capacity, not a catalyst (GlobeNewswire — Nautilus Biotechnology to announce Q3 2026 results on October 27, TheFly — Nautilus Biotechnology files $300M mixed securities shelf). The company has first revenue on the books from its Voyager single-molecule proteomics platform and cash runway disclosed into 2028, which is the fundamental case the sell-side is underwriting — but none of that changed on Monday. A 28% gain on double normal volume, one week before earnings, in a name that had just given back 8% over five sessions and sits 39% below its 52-week high of $4.31, reads as pre-print positioning in a low-float equity on a day the small-cap biotech proxy rose 2.45%. Its Genetics & Genomics bucket averaged +5.47% (n=6), so roughly a fifth of the move is bucket beta; the rest is not explained by anything the company said. Flagged: no clean catalyst.

ADGM — Adagio Medical, +21.21% to $0.12 on 0.92x volume

Adagio Medical Holdings closed at $0.12, up 21.21% from $0.099, on 3.25 million shares — and the volume ratio is the whole story: 0.92x, meaning the gain came on below-average turnover. No same-day press release, filing or clinical disclosure was identified. The operative backdrop is structural rather than informational. On September 23 the board launched a formal strategic review covering a possible sale, merger, business combination or other transaction, paired with a workforce reduction to align cost structure with prioritized programs, against roughly $7.7 million of cash, equivalents and marketable securities as of June 30 (StockTitan — Adagio Medical begins formal strategic review process). And on October 23 — four sessions after Monday — stockholders vote on charter amendments authorizing a reverse split of anywhere from 1-for-10 to 1-for-500, with the board choosing both the ratio and whether to proceed at all (StockTitan — Adagio Medical proposes 1-for-10 to 1-for-500 reverse split, Kalkine — Adagio Medical announces special stockholder meeting to approve reverse stock split).

A 21% move in a 12-cent stock on light volume, four days before a reverse-split vote, in a company that has publicly hung a for-sale sign on itself, is a spread-and-positioning print against a lottery ticket — not a repricing of anything disclosed Monday. The stock closed at $0.12 inside a recorded range of $0.08–$1.69, -23.9% over five sessions and within four cents of its own low. In a name like this a single cent is 8% of the price; the percentage is describing the tick, not the company. Its Devices – Miscellaneous bucket averaged +1.97% (n=26), so the move is 19.2 points above bucket. Flagged: no clean catalyst.

Top 3 Losers — What Drove Them

EYPT — EyePoint, -85.28% to $0.44 on 56.09x volume

EyePoint collapsed to $0.44, down 85.28% from $2.99, on 184.15 million shares — a 56.09x volume ratio, the largest relative print in the entire 570-name universe and roughly a fifth of the company’s market value changing hands in a single session. The trigger was a second pivotal failure for DURAVYU, the company’s intravitreal vorolanib insert: the Phase 3 program in wet age-related macular degeneration missed its primary endpoint, and management responded the same morning by terminating the late-stage wet AMD trials, cutting approximately 53% of the workforce, and redirecting what remains toward diabetic macular edema (Yahoo Finance — EyePoint Pharmaceuticals to cut 53% of workforce after eye disease drug failure, Barchart — EYPT stock layoffs: what to know about the latest EyePoint job cuts, Seeking Alpha — EyePoint stock down on late-stage trial setback, AInvest — EyePoint’s wet AMD drug missed the bar twice; now the stock trades below cash).

The residual equity now trades below the cash on the balance sheet, which is the market’s statement that the remaining DME program and the restructuring cost more to finish than they are worth at current probabilities. The first securities-litigation notice arrived the same day, with Levi & Korsinsky announcing a shareholder investigation into the DURAVYU disclosures (PR Newswire — Levi & Korsinsky investigation notice, October 19, 2026). Note the five-day column: -12.1% into a -85.28% session. This was not a slide that accelerated; it was a cliff under a stock that had already been drifting lower. The close at $0.44 sits far below the recorded 52-week range of $2.93–$19.11 — a fresh low by a wide margin, and a name that had no sector category in our classification, so there is no bucket average to compare it against. Class 2 — single-stock binary catalyst, in its terminal form: the program the equity was built on is gone.

LNAI — Lunai Bioworks, -30.62% to $0.4721 on 2.51x volume

Lunai Bioworks closed at $0.4721, down 30.62% from $0.68, on just 202,974 shares — a 2.51x ratio off a microscopic base, in a company whose entire market capitalization is now roughly $2.1 million. No same-day press release, filing or data disclosure was identified. The freshest hard items are at least a week old and point in the same direction rather than explaining Monday specifically. On October 9 the company asked Nasdaq to suspend trading in its own common stock while authorities review trading records surfaced in discovery from its Delaware litigation against Seven Points Capital and others; its October 13 annual report then rewrote the business description around BioSymetrics, Renovaro Biosciences and a new IP-holding subsidiary for Neurobridge assets (Panabee — Lunai Bioworks requests Nasdaq trading suspension citing alleged market manipulation, TipRanks — Lunai Bioworks seeks Nasdaq trading suspension amid probe, Substack — Lunai Bioworks 10-K: business changes lead).

With $2.1 million of market value, a 1-for-8 reverse split completed in May 2026 to cure a listing deficiency, and no operating revenue, a 31% decline on 203,000 shares is illiquidity and event overhang, not a new fact. The stock is -44.7% over five sessions and closed at $0.4721 against a recorded 52-week range of $0.66–$13.28 — another fresh low outside the recorded band. Its AI / Machine Learning bucket lost -3.65% on average (n=6) while that same bucket’s median was +3.89% — the widest average-to-median gap in the sector table, and a warning that a six-name bucket’s average is a description of its outliers, not its centre. Flagged: no clean catalyst.

LUCD — Lucid Diagnostics, -21.05% to $0.3774 on 2.43x volume

Lucid Diagnostics closed at $0.3774, down 21.05% from $0.478, on 4.27 million shares — a 2.43x volume ratio that extended a -25.1% five-day loss. No same-day press release or filing was identified. The dominant recent fact is regulatory: on October 12 Nasdaq notified the company that its closing bid had sat below the $1.00 minimum for 30 consecutive business days, giving it 180 calendar days — until April 12, 2027 — to regain compliance by closing at or above $1.00 for ten consecutive sessions (StockTitan — Lucid Diagnostics gets April 12, 2027 Nasdaq deadline, Trendonify — Lucid Diagnostics receives Nasdaq delisting notice, Simply Wall St — Lucid Diagnostics future).

The operating story is genuinely improving on paper and the market is not paying for it. The company reported EsoGuard revenue of $1.47 million in the second quarter, up from $1.16 million a year earlier on 2,770 tests; the AMA CPT Editorial Panel approved a new Category III code covering non-endoscopic esophageal cell collection with EsoCheck; a Medicare advisory panel recommended maintaining EsoGuard’s gapfill payment basis with final CMS determinations expected in November; and a first laboratory benefit manager coverage policy now deems EsoGuard medically necessary for eligible patients (StockTitan — Lucid Diagnostics advances multiple EsoGuard and EsoCheck payment, billing and coding pathways). Against that, the capital structure is unforgiving: $33.4 million of cash at June 30 against a $14.3 million quarterly operating expense run rate, and an April offering of 18 million shares priced at $1.00 — nearly three times Monday’s close (PR Newswire — Lucid Diagnostics announces $18 million underwritten offering). The close at $0.3774 is a fresh low against a recorded range of $0.47–$1.63, and the Diagnostics bucket finished -1.18% (n=28) — the weakest of the large therapeutic buckets on a day the sector rose. Flagged: no clean same-day catalyst; the honest read is listing-mechanics selling plus financing overhang ahead of a November reimbursement decision.

The Cross-Cutting Pattern

The rotation on Monday was within health care, not into it, and that distinction is the day’s real content. XLV -0.60% against XBI +2.45% is a 3.05-point spread between two proxies that usually move together, and it resolves cleanly: the equal-weighted small-cap index is dominated by clinical-stage companies whose value is a function of pipeline probability, while the sector index is dominated by large-cap pharma, medtech and services whose value is a function of earnings and policy. On a day with no macro catalyst and an S&P up only 0.44%, the marginal dollar went to the part of health care with the highest duration on scientific outcomes and the lowest duration on 2027 revenue. Our internal buckets confirm it from a second angle: Genetics & Genomics +5.47% (n=6), Antibodies +2.66% (n=42), RNA, Peptide & Gene Therapy +2.41% (n=27) and Biologics +1.66% (n=84) all outran the sector, while Diagnostics -1.18% (n=28) and Drug Delivery/Formulation -0.64% (n=28) lagged. That is the classic risk-on configuration inside biotech: platform and mechanism stories bid, tools-and-testing stories offered.

But the second half of the pattern is what makes Monday unusual, and it is a caution against reading the rotation as the explanation for the leaderboard. The day’s two extremes were not rotation trades — they were the same trade, on opposite sides of the same coin. Disc Medicine’s APOLLO win and EyePoint’s DURAVYU failure are both single-readout repricings of a single asset, and together they account for 124.1 points of the day’s spread while the sector index moved 2.45%. Four of the other leaders and laggards — NAUT, ADGM, LNAI, LUCD — had no same-day company disclosure at all, and three of those four moved on volume ratios between 0.92x and 2.51x, which is not the footprint of institutional repositioning. The pattern, then, is a broad, orderly bid for clinical-stage biotech punctuated by two violent idiosyncratic repricings and four microcap prints that the bid neither caused nor explained. The middle of the distribution — 557 directional names, a +0.85% median, a 1.49-to-1 ratio — is where the rotation lives. The tails are where the science lives.

The 5 Data Points That Matter

1. Percentage change versus the sector mean. The centre of the distribution sat at +0.85%. Disc Medicine’s +38.86% is 38.0 points above the median and 36.2 points above its own Antibodies bucket at +2.66% (n=42); Nautilus’ +27.67% is 26.8 points above the median and 22.2 points above Genetics & Genomics at +5.47% (n=6); Adagio’s +21.21% is 20.4 points above the median and 19.2 points above Devices – Miscellaneous at +1.97% (n=26). On the losing side EyePoint’s -85.28% is 86.1 points below the median; Lunai’s -30.62% is 31.5 points below and 27.0 points below its AI / Machine Learning bucket at -3.65% (n=6); Lucid’s -21.05% is 21.9 points below and 19.9 points below Diagnostics at -1.18% (n=28). The widest bucket dispersion among samples of ten or more was 4.3 points — from Antibodies +2.66% to Diagnostics -1.18% — against a 124.1-point single-name spread. No sector call can explain a 124-point range.

2. Volume ratio. This column separated information from mechanics more cleanly than price did. EyePoint’s 56.09x on 184.15 million shares is real, enormous turnover behind a genuine binary failure — the largest absolute share volume in the dataset by a factor of four, and the only print on the board where the ratio and the dollar volume agree. Disc Medicine’s 13.29x on 8.49 million shares is the same signature on the winning side. Below that the ratios fall away fast and stop corroborating the price: CytoSorbents 7.10x on 255,886 shares, Marker Therapeutics 5.10x on 580,081, Alaunos 2.69x on 41.2 million, Nautilus 2.08x — and then Adagio at 0.92x, a 21% gain on below-average turnover. The stealth row was thin and almost entirely negative-skewed on price: Instil Bio -2.03% at 6.87x, Vivos Therapeutics +2.90% at 6.72x on 41.5 million shares, 20/20 BioLabs -0.12% at 4.59x, Dogwood Therapeutics -0.82% at 3.32x. Four names, three of them flat-to-down on heavy volume — distribution, not accumulation.

3. Five-day momentum. Monday’s extremes split into two clean binary breaks and four reversals or continuations inside existing trends. Disc Medicine -8.4% over five days into +38.86% and EyePoint -12.1% into -85.28% are single-session events landing on drifting weeks — exactly what a same-day readout produces, and the only two of the six where the five-day column is irrelevant to the explanation. Nautilus -8.4% into +27.67% and Adagio -23.9% into +21.21% are both bounces inside downtrends, which is what a 28% and a 21% gain look like when nothing has changed. Lunai -44.7% into -30.62% and Lucid -25.1% into -21.05% are pure continuations — the only two of the six that needed neither an announcement nor a reversal to explain them, and the two whose declines are most likely to persist.

4. Position in range and absolute price. Five of the six extremes trade under $2.63 and three trade under fifty cents: EyePoint at $0.44 (recorded range $2.93–$19.11, a fresh low by a wide margin), Adagio at $0.12 ($0.08–$1.69, four cents off its low), Lucid at $0.3774 ($0.47–$1.63, below the recorded low), Lunai at $0.4721 ($0.66–$13.28, also below the recorded low) and Nautilus at $2.63 ($0.84–$4.31, 39% below its high). Only Disc Medicine at $78.93 closed mid-to-upper range in a $40.00–$99.50 band — the single name on the leaderboard whose price is a judgement about a franchise rather than a tick about a float. Three of the six closed below the lowest price recorded for them in this dataset. For four of the six, a one-cent move is between 2% and 8% of the share price, which is precisely why their percentages describe liquidity, not value.

5. Cash and dilution context. Six extremes, and not one is trading on a balance sheet that lets the science speak for itself. EyePoint is now valued below its cash and is funding a DME pivot on roughly 47% of its former headcount. Lucid holds $33.4 million against a $14.3 million quarterly burn, carries an 18-million-share offering priced at $1.00, and has 180 days to cure a sub-$1.00 bid. Adagio has ~$7.7 million of liquidity, a strategic review with no timetable, and a reverse-split authorization up to 1-for-500 on the ballot four days out. Lunai is a $2.1 million market cap that already executed a 1-for-8 split in May and has asked the exchange to halt its own stock. Nautilus has runway disclosed into 2028 and a $300 million shelf it has not drawn. And Disc Medicine — the only winner with a real catalyst — used the readout to buy itself an NDA filing, which is the cheapest form of capital a clinical-stage company can raise: the kind it does not have to raise.

What This Synthesis Will and Won’t Tell You

This is a one-day reading and should be read as one. It tells you what moved and why — the 118 anomaly-flagged names, the six data-defined extremes, the signal class behind each, and the cross-cutting pattern: a broad, orderly bid for clinical-stage biotech (333 advancers against 224 decliners, a +0.85% median, XBI +2.45% against XLV -0.60% and an S&P 500 at +0.44%) in which the two largest moves in either direction were a Phase 3 win and a Phase 3 failure, and four of the six extremes carried no same-day company disclosure at all. It does not tell you what happens next: whether Disc Medicine’s APOLLO data survive the FDA’s review of an NDA it has not yet filed, or whether $78.93 already discounts a clean approval; whether EyePoint’s DME pivot is fundable on a share price below cash, or whether $0.44 is a liquidation value with a litigation tail; whether Nautilus trades through its October 27 print on the strength of a franchise case or gives back a 28% move that has no company news behind it; whether Adagio’s strategic review produces a transaction before the October 23 reverse-split vote re-bases the share count; and whether Lucid’s November CMS determination arrives in time to matter to a stock with 180 days of listing runway.

The honest limits are four. First, the catalyst investigation covers the six data-defined top movers only, and the rest of the anomaly board carries stories that are noted here but not investigated — several deserve their own line: CytoSorbents +20.68% on 7.10x (a second consecutive double-digit session, now +8.4% over five days), Alaunos +19.01% on 41.2 million shares (still +234.7% over five days, the acquisition-and-financing print still working), Marker Therapeutics +15.38% on 5.10x, Agios +11.43%, Arcutis +10.65%, and on the losing side PDS Biotechnology -18.89% on 0.24x volume, XORTX -18.55% on 0.08x, NeuroSense -13.19% on 5.18x, Atossa -12.03%, Karyopharm -11.30% (still -35.5% over five days), Cellectis -11.01% and Fractyl Health -10.97% (now -64.9% over five days, the second session of its post-REMAIN-1 unwind). Second, three of the six extremes had no clean same-day catalyst — Nautilus, Adagio and Lunai are flagged rather than assigned narratives, and Lucid is labelled a continuation rather than an event. Those four are included because the data placed them on the leaderboard; the labels are the correction, not a substitute for them. Third, sector averages built on small samples are not averages. Genetics & Genomics (n=6) leads the table on six companies, AI / Machine Learning (n=6) shows a -3.65% average against a +3.89% median, and Nanotechnology (n=3) at -5.64% is three names — none of those is a sector verdict. The meaningful reads are Antibodies +2.66% (n=42), RNA, Peptide & Gene Therapy +2.41% (n=27), Biologics +1.66% (n=84), Small Molecule Pharma +1.24% (n=150) and Diagnostics -1.18% (n=28). Fourth, one broad up-day cannot distinguish a durable rotation into clinical-stage risk from a single-session reversal of Friday’s uniform de-risking. Friday’s session was 492 decliners against 71 advancers on a -3.52% median with every one of 24 buckets negative; Monday was 333 advancers against 224 on a +0.85% median with the clinical buckets leading. Two sessions, two extremes, and a standard deviation that stayed in the same 5.5–6.2% band throughout — that is a market oscillating around a wide distribution, not one that has changed its mind, and the third-quarter reporting window runs through late October and November.

---

This is editorial analysis, not investment advice. Single-day returns reflect regular-session closing prices on 2026-10-19 and will change with market conditions, clinical readouts, financing terms and regulatory events. Micro-cap and clinical-stage names can experience rapid reversals; several of the names discussed here trade under $5.00, carry pending capital, listing-compliance or going-concern disclosures, or have outstanding offerings, reverse splits and securities litigation, and readers should review the underlying filings before drawing conclusions about momentum durability.

Generated 2026-10-19 PT (post-market, after the 4 PM ET close). Market data compiled from public quote and historical market-data feeds; sector categorisation from public company filings and listings; company backgrounds compiled from public investor disclosures and press releases. For the prior synthesis, see Daily Biotech Movers — 2026-10-16.

Sources: [Disc Medicine — APOLLO Phase 3 topline results in erythropoietic protoporphyria and corporate webcast, 2026-10-19]; [EyePoint Pharmaceuticals — DURAVYU Phase 3 wet AMD topline results, trial discontinuation and restructuring, 2026-10-19]; [Levi & Korsinsky — EyePoint Pharmaceuticals investigation notice, 2026-10-19]; [Nautilus Biotechnology — third-quarter 2026 results scheduled for October 27, 2026-10-15]; [Nautilus Biotechnology — $300 million mixed securities shelf registration, 2026-09-11]; [Adagio Medical Holdings — formal strategic review process, 2026-09-23]; [Adagio Medical Holdings — definitive proxy for special meeting on reverse stock split, 2026-10-23]; [Lucid Diagnostics — Nasdaq minimum bid price notice, 2026-10-12]; [Lucid Diagnostics — EsoGuard and EsoCheck payment, billing and coding pathway update, 2026-09-22]; [Lucid Diagnostics — second quarter 2026 results, 2026-08-13]; [Lunai Bioworks — request for Nasdaq trading suspension, 2026-10-09]; [Lunai Bioworks — annual report business description update, 2026-10-13]; public quote and historical market-data feeds; company investor-relations disclosures.